Inventor

LAN JIANG

Inventor

US

Overview

2021–2025

Patent span

Human necessities

Primary field (CPC A)

Patents· 31 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Pprimary

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations23%

C07DHeterocyclic compounds22%

A61KPreparations for medical, dental or toiletry purposes20%

B23KSoldering or unsoldering4%

C07KPeptides3%

B82YSpecific uses or applications of nanostructures2%

C07BGeneral methods of organic chemistry2%

C07CAcyclic or carbocyclic compounds2%

Y02ATechnologies for adaptation to climate change2%

A01BSoil working in agriculture or forestry1%

PatentTitleYear

12,421,235Bridged tricyclic carbamoylpyridone compounds and uses thereof2025 RE050554Amino acid compounds and methods of use2025 12,246,393Femtosecond laser system for processing micro-hole array2025 12,227,520Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use2025 12,217,857Public event administrating system2025 D1060019Pole head2025 12,202,842MCL1 inhibitors2025 12,187,734Substituted pyridotriazine compounds and uses thereof2025 12,162,844MCL-1 inhibitors2024 12,150,992Multifunctional therapeutic biological material and preparation method thereof2024 12,122,776Tetracyclic compounds and uses thereof2024 12,054,496Bridged tricyclic carbamoylpyridone compounds and uses thereof2024 12,024,528Bridged tricyclic carbamoylpyridone compounds and uses thereof2024 11,897,892Substituted pyridotriazine compounds and uses thereof2024 11,718,616JAK kinase inhibitor compounds for treatment of respiratory disease2023 11,697,652Tetracyclic compounds and uses thereof2023 11,673,887N-acyl amino acid compounds and methods of use2023 11,667,652MCL1 inhibitors2023 11,643,400MCL-1 inhibitors2023 11,634,418Amino acid compounds and methods of use2023 11,613,546Substituted pyridotriazine compounds and uses thereof2023 11,560,376Amino acid compounds and methods of use2023 11,548,902Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use2023 11,548,8878-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists2023 11,547,039Fully-automatic transplanting combined machine2023 11,352,261Graphene-MXene nanoflower composite material, preparation method and application thereof2022 11,313,971Three-dimensional imaging system and method2022 11,299,492JAK kinase inhibitor compounds for treatment of respiratory disease2022 11,253,953Method and device for processing unidirectional flow surface2022 11,221,437Protein-matrix microlens array diffraction device and method for preparing the same2022 11,160,810Fused imidazo-piperidine JAK inhibitor compound2021

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2021–2023Patents assigned to THERAVANCE BIOPHARMA R&D IP LLC (4)· patent assignee history

2021–2025Based in US· patent location history

2022–2024Patents assigned to BEIJING INSTITUTE TECH (4)· patent assignee history

2022–2025Patents assigned to UNIV TSINGHUA (2)· patent assignee history

2022–2025Based in CN· patent location history

2023–2025Patents assigned to GILEAD SCIENCES INC (14)· patent assignee history

2023–2025Patents assigned to PLIANT THERAPEUTICS INC (4)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
GILEAD SCIENCES INC	14	2023–2025
BEIJING INSTITUTE TECH	4	2022–2024
PLIANT THERAPEUTICS INC	4	2023–2025
THERAVANCE BIOPHARMA R&D IP LLC	4	2021–2023
UNIV TSINGHUA	2	2022–2025

Locations

Location	Patents	Span
US	22	2021–2025
CN	9	2022–2025